![Frank Harder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Frank Harder
No más puestos en curso
Perfil
Frank Harder formerly worked at Bioporto A, as Chief Financial Officer & IR Contact from 2007 to 2014, Zymenex A, as Chief Financial Officer, and PhaseOneTrials A, as Chief Financial Officer.
Mr. Harder received his graduate degree from the University of Copenhagen.
Antiguos cargos conocidos de Frank Harder.
Empresas | Cargo | Fin |
---|---|---|
BIOPORTO A/S | Director Financiero/CFO | 01/01/2014 |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Director Financiero/CFO | - |
PhaseOneTrials A/S
![]() PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease. | Director Financiero/CFO | - |
Formación de Frank Harder.
University of Copenhagen | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BIOPORTO A/S | Health Technology |
Empresas privadas | 2 |
---|---|
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Health Technology |
PhaseOneTrials A/S
![]() PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease. | Commercial Services |
- Bolsa de valores
- Insiders
- Frank Harder